Catalent today announced that it had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the Shiga prefecture of Japan.

Catalent announced a deal to acquire a clinical packaging facility in Minakuchi, located in the Shiga prefecture of Japan, from Teva-Takeda Pharmaceuticals, Nagoya Aichi, Japan.

Catalent today announced that it will present at the upcoming conference, ‘Outsourcing in Clinical Trials 2020 – A Virtual Experience’.

Catalent today welcomed the news by Humanigen, Inc., that it has dosed the first COVID-19 patient in its previously announced Phase 3 study for lenzilumab.

Catalent today announced that two of its experts will present at upcoming virtual industry conferences: CPhI North America Webinar Week; and Clinical Trial Supply 2020 – A Virtual Experience.

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents for its health and safety practices, achieving a silver award for a second consecutive year.

Catalent today announced the appointment of Ricci Whitlow as President, Clinical Supply Services. Ms. Whitlow succeeds Paul Hegwood, who plans to retire in March 2020.

Catalent, a global leader in clinical supply services, today announced the launch of FlexDirect™, a new direct-to-patient service for clinical trials.

Catalent was recently awarded a certificate of recognition from the Tangzhen, China government to acknowledge the company’s successful investment and operations in the region.